Risk factors analysis and construction of predictive models for acute kidney injury in overweight patients receiving vancomycin treatment

被引:0
作者
Hong, Huadong [1 ]
Chen, Yichen [1 ]
Zhou, Ling [2 ]
Bao, Jian'an [1 ]
Ma, Jingjing [1 ]
机构
[1] Soochow Univ, Med Ctr Soochow Univ, Dept Pharm, Affiliated Hosp 4, Suzhou, Peoples R China
[2] Soochow Univ, Dept Pharm, Affiliated Hosp 1, Suzhou, Peoples R China
基金
中国国家自然科学基金;
关键词
Vancomycin; acute kidney injury; therapeutic drug monitoring; risk factors; prediction model; STAPHYLOCOCCUS-AUREUS INFECTIONS; REVISED CONSENSUS GUIDELINE; HEALTH-SYSTEM PHARMACISTS; INDUCED NEPHROTOXICITY; DISEASES SOCIETY; OBESE-PATIENTS; AMERICAN SOCIETY; PHARMACOKINETICS; AMINOGLYCOSIDE; METAANALYSIS;
D O I
10.1080/14740338.2024.2393285
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background Vancomycin-induced acute kidney injury (VI-AKI) is one of its serious adverse reactions. The purpose of this study is to discuss the risk factors for VI-AKI in overweight patients and construct a clinical prediction model based on the results of the analysis. Methods Multivariable logistic regression analysis was used to identify risk factors for VI-AKI and constructed nomogram models. The performance of the nomogram was evaluated based on the area under the receiver operating characteristic curve (AUC), calibration curves, and decision curve analysis (DCA). Result Cancer (OR 4.186, 95% CI 1.473-11.896), vancomycin trough concentration >20.0 mu g/mL (OR 6.251, 95% CI 2.275-17.180), concomitant furosemide (OR 2.722, 95% CI 1.071-6.919) and vasoactive agent (OR 2.824, 95% CI 1.086-7.340) were independent risk factors for VI-AKI. The AUC of the nomogram validation cohorts were 0.807 (95% CI 0.785-0.846). The calibration curve revealed that the predicted outcome was in agreement with the actual observations. Finally, the DCA curves showed that the nomogram had a good clinical applicability value. Conclusion There are four independent risk factors for the occurrence of VI-AKI in overweight patients, and the nomogram prediction model has good predictive ability, which can provide reference for clinical decision-making.
引用
收藏
页数:10
相关论文
共 48 条
[1]   Pharmacokinetics of Vancomycin in Extremely Obese Patients with Suspected or Confirmed Staphylococcus aureus Infections [J].
Adane, Eyob D. ;
Herald, Michael ;
Koura, Firas .
PHARMACOTHERAPY, 2015, 35 (02) :127-139
[2]   Effect of N-acetylcysteine against Vancomycin-Induced Nephrotoxicity: A Randomized Controlled Clinical Trial [J].
Badri, Shirinsadat ;
Soltani, Rasool ;
Sayadi, Mina ;
Khorvash, Farzin ;
Meidani, Mohsen ;
Taheri, Shahram .
ARCHIVES OF IRANIAN MEDICINE, 2020, 23 (06) :397-402
[3]   Evaluation of a modified vancomycin nomogram for obese adults [J].
Batchelder, Nathan ;
Lutheran, Carrie Faith ;
Frens, Jeremy .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 76 (03) :403-408
[4]   Kidney biopsy findings in vancomycin-induced acute kidney injury: a pooled analysis [J].
Bellos, Ioannis ;
Pergialiotis, Vasilios ;
Perrea, Despina N. .
INTERNATIONAL UROLOGY AND NEPHROLOGY, 2022, 54 (01) :137-148
[5]  
Brogan M., 2007, Yearb Med, V2007, P211, DOI [10.1016/S0084-3873(08)70142-1, DOI 10.1016/S0084-3873(08)70142-1]
[6]   Risk Factors for Acute Kidney Injury in Adult Patients Receiving Vancomycin [J].
Cappelletty, Diane ;
Jablonski, Alyse ;
Jung, Rose .
CLINICAL DRUG INVESTIGATION, 2014, 34 (03) :189-193
[7]   Comparative Incidence of Nephrotoxicity by Age Group among Adult Patients Receiving Vancomycin [J].
Carreno J.J. ;
Jaworski A. ;
Kenney R.M. ;
Davis S.L. .
Infectious Diseases and Therapy, 2013, 2 (2) :201-208
[8]   RELATIONSHIP OF SERUM ANTIBIOTIC CONCENTRATIONS TO NEPHROTOXICITY IN CANCER-PATIENTS RECEIVING CONCURRENT AMINOGLYCOSIDE AND VANCOMYCIN THERAPY [J].
CIMINO, MA ;
ROTSTEIN, C ;
SLAUGHTER, RL ;
EMRICH, LJ .
AMERICAN JOURNAL OF MEDICINE, 1987, 83 (06) :1091-1097
[9]   Assessment of initial vancomycin trough levels and risk factors of vancomycin-induced nephrotoxicity in neonates [J].
Dawoud, Tasnim Heider ;
Khan, Nusrat ;
Afzal, Uzma ;
Varghese, Nisha ;
Rahmani, Aiman ;
Abu-Sa'da, Omar .
EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2022, 29 (01) :44-49
[10]   Risk factors for acute kidney injury during aminoglycoside therapy in patients with cystic fibrosis [J].
Downes, Kevin J. ;
Patil, Neha R. ;
Rao, Marepalli B. ;
Koralkar, Rajesh ;
Harris, William T. ;
Clancy, John P. ;
Goldstein, Stuart L. ;
Askenazi, David J. .
PEDIATRIC NEPHROLOGY, 2015, 30 (10) :1879-1888